In a Spanish Lung Cancer Group ( SLCG ) phase II trial , the combination of BRCA1 and receptor-associated protein 80 ( RAP80 ) expression was significantly associated with outcome in Caucasian patients with nonsmall-cell lung cancer ( NSCLC ) .